Emerging clinical evidence suggests that modified BXD demonstrates therapeutic efficacy in ameliorating insulin sensitivity and restoring reproductive endocrine balance in patients with PCOS-associated IR (PCOS-IR). The gene discussed is INS; the disease is polycystic ovary syndrome.